Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Endocrinology · Classic Congenital Adrenal Hyperplasia, Simple Virilizing Form

Managing Treatment: The Balancing Act

At a Glance

Treating simple virilizing CAH requires balancing glucocorticoids to replace missing hormones while avoiding side effects. Doctors monitor treatment success not just with morning blood tests, but by tracking physical growth and bone age to prevent early puberty or stunted growth.

Treating the Simple Virilizing (SV) form of CAH is a careful balancing act. The goal is to give the body enough medicine to replace what it cannot make, while keeping “extra” hormones in check without causing side effects [1][2].

The Core Treatment: Glucocorticoids

The primary treatment is glucocorticoid replacement therapy, usually in the form of hydrocortisone for children [3][4]. Because hydrocortisone is short-acting, it is typically taken three times a day to mimic the body’s natural rhythms [3].

As patients transition to adulthood, doctors often switch them to longer-acting glucocorticoids, such as dexamethasone or prednisone, or modified-release hydrocortisone, which can simplify dosing schedules [5][6].

The “balancing act” involves two main risks:

  • Undertreatment: If the dose is too low, the adrenal glands will overproduce androgens. This can lead to virilization (early puberty signs), rapid but short-lived growth, and the risk of a life-threatening adrenal crisis [7][8].
  • Overtreatment: If the dose is too high, it can lead to iatrogenic Cushing syndrome. Signs include excessive weight gain, a rounded face, and—most importantly in children—slowed or stunted growth [1][9][10].

Why Lab Results Aren’t the Whole Story

Doctors monitor treatment using blood tests for 17-hydroxyprogesterone (17-OHP) and androstenedione [11]. However, these levels fluctuate significantly throughout the day [12][13].

Important Lab Timing: To get accurate results, blood tests typically must be drawn first thing in the morning, before taking the morning dose of medication [12][14].

  • No “Perfect” Number: There is no single universal target number for these hormones. A level that is “too high” on paper might be acceptable if the child is growing normally [15][9].
  • Clinical Picture: Doctors rely more on physical progress than lab results alone. They track growth velocity (how many inches a child grows per year) and bone age (an X-ray of the hand to see if the bones are maturing too fast) [16][17][18].

Salt Balance and Fludrocortisone

In the “Simple Virilizing” form, the body can usually make enough aldosterone to keep salt levels stable [19][20]. However, some SV patients may still have a partial deficiency.

  • Fludrocortisone: This is a medication that acts like aldosterone. While it is mandatory for the “salt-wasting” form, it is used more selectively in SV-CAH [21][22].
  • Renin Monitoring: Doctors may check plasma renin activity (PRA). If renin is high, it means the body is struggling to maintain salt balance, and adding a small dose of fludrocortisone might help “calm” the adrenal glands, potentially allowing for a lower dose of hydrocortisone [21][23].

Stress Dosing and Emergencies

Because patients with CAH cannot produce their own “stress” cortisol, they must practice stress dosing. During times of high fever, severe injury, or surgery, the daily dose of hydrocortisone must be doubled or tripled [24][25]. For severe emergencies (like vomiting where pills can’t be kept down), an injectable form of hydrocortisone must be used [26][27].

New treatments, such as CRF1 receptor antagonists (e.g., crinecerfont), are currently being studied as “steroid-sparing” therapies that may help lower the amount of glucocorticoids needed in the future [28][29].

Common questions in this guide

Why do I need to take my CAH blood test before my morning medication?
Blood tests for 17-OHP and androstenedione fluctuate significantly throughout the day based on your medication schedule. Drawing blood first thing in the morning before your dose gives your endocrinologist the most accurate baseline of your hormone levels.
What happens if my SV-CAH medication dose is too high?
Overtreatment with glucocorticoids can lead to iatrogenic Cushing syndrome. Common signs include excessive weight gain, a rounded face, and most importantly, slowed or stunted physical growth in children.
What are the signs of undertreatment in simple virilizing CAH?
If your medication dose is too low, the adrenal glands will overproduce androgens. This can cause early signs of puberty, rapid but short-lived growth, and a higher risk of experiencing a life-threatening adrenal crisis.
How do doctors know if my child's CAH treatment is working?
Doctors look at more than just hormone levels on a lab report. They carefully track your child's physical growth velocity over time and use hand X-rays to check if bone age is advancing faster than your child's actual age.
When is a stress dose of hydrocortisone needed?
Because CAH patients cannot produce extra cortisol naturally, stress dosing is required during times of severe physical stress, such as a high fever, severe injury, or surgery. During these events, the daily dose of hydrocortisone must be doubled or tripled to prevent an emergency.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's current growth velocity, and how does it compare to the 'normal' curve for their age?
  2. 2.When was the last bone age X-ray, and is the bone age advancing faster than the child's actual age?
  3. 3.Given the timing of our blood draws, what hormone levels (17-OHP or androstenedione) are you specifically targeting?
  4. 4.Is there any evidence of mineralocorticoid deficiency that would require us to start or increase fludrocortisone?
  5. 5.Are there newer 'steroid-sparing' treatments (like CRF1 receptor antagonists) that might be appropriate for us in the future?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (29)
  1. 1

    Hydrocortisone dosing in children with classic congenital adrenal hyperplasia: results of the German/Austrian registry.

    Hoyer-Kuhn H, Huebner A, Richter-Unruh A, et al.

    Endocrine connections 2021; (10(5)):561-569.

    PMID: 33909597
  2. 2

    Management challenges and therapeutic advances in congenital adrenal hyperplasia.

    Mallappa A, Merke DP

    Nature reviews. Endocrinology 2022; (18(6)):337-352 doi:10.1038/s41574-022-00655-w.

    PMID: 35411073
  3. 3

    Practice Variation among Pediatric Endocrinologists in the Dosing of Glucocorticoids in Young Children with Congenital Adrenal Hyperplasia.

    Al-Rayess H, Lahoti A, Simpson LL, et al.

    Children (Basel, Switzerland) 2023; (10(12)) doi:10.3390/children10121871.

    PMID: 38136073
  4. 4

    A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules.

    Neumann U, Braune K, Whitaker MJ, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(3)):e1433-e1440 doi:10.1210/clinem/dgaa626.

    PMID: 32888021
  5. 5

    Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

    Bornstein SR, Allolio B, Arlt W, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(2)):364-89 doi:10.1210/jc.2015-1710.

    PMID: 26760044
  6. 6

    Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion].

    Yanase T, Tajima T, Katabami T, et al.

    Endocrine journal 2016; (63(9)):765-784 doi:10.1507/endocrj.EJ16-0242.

    PMID: 27350721
  7. 7

    Two girls with a neonatal screening-negative 21-hydroxylase deficiency requiring treatment with hydrocortisone for virilization in late childhood.

    Onuma S, Fukuoka T, Miyoshi Y, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2021; (30(3)):143-148 doi:10.1297/cpe.30.143.

    PMID: 34285457
  8. 8

    Quality of compounded hydrocortisone capsules used in the treatment of children.

    Neumann U, Burau D, Spielmann S, et al.

    European journal of endocrinology 2017; (177(2)):239-242.

    PMID: 28512133
  9. 9

    Height Velocity Defined Metabolic Control in Children With Congenital Adrenal Hyperplasia Using Urinary Steroid GC-MS Analysis.

    Kamrath C, Wettstaedt L, Hartmann MF, Wudy SA

    The Journal of clinical endocrinology and metabolism 2019; (104(9)):4214-4224 doi:10.1210/jc.2019-00438.

    PMID: 31112272
  10. 10

    Congenital adrenal hyperplasia: New biomarkers and adult treatments.

    Dreves B, Reznik Y, Tabarin A

    Annales d'endocrinologie 2023; (84(4)):472-480 doi:10.1016/j.ando.2023.01.008.

    PMID: 36842612
  11. 11

    Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry.

    Lawrence N, Bacila I, Dawson J, et al.

    Clinical endocrinology 2022; (97(5)):551-561 doi:10.1111/cen.14796.

    PMID: 35781728
  12. 12

    Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

    Debono M, Mallappa A, Gounden V, et al.

    European journal of endocrinology 2015; (173(6)):727-37 doi:10.1530/EJE-15-0064.

    PMID: 26340969
  13. 13

    An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.

    Al-Kofahi M, Ahmed MA, Jaber MM, et al.

    British journal of clinical pharmacology 2021; (87(3)):1098-1110 doi:10.1111/bcp.14470.

    PMID: 32652643
  14. 14

    Current insights into monitoring of congenital adrenal hyperplasia.

    Leusink QM, Verploegen EEW, Adriaansen BPH, et al.

    Frontiers in endocrinology 2026; (17()):1774145 doi:10.3389/fendo.2026.1774145.

    PMID: 41767372
  15. 15

    Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

    Speiser PW, Arlt W, Auchus RJ, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(11)):4043-4088 doi:10.1210/jc.2018-01865.

    PMID: 30272171
  16. 16

    The utility of annual growth velocity standard deviation scores and measurements of biochemical parameters in long-term treatment monitoring of children with 21-hydroxylase deficiency.

    Ozdemir Dilek S, Turan I, Gurbuz F, et al.

    Hormones (Athens, Greece) 2022; (21(3)):391-397 doi:10.1007/s42000-022-00354-1.

    PMID: 35243601
  17. 17

    Quantitative targeted GC-MS-based urinary steroid metabolome analysis for treatment monitoring of adolescents and young adults with autoimmune primary adrenal insufficiency.

    Kamrath C, Hartmann MF, Wudy SA

    Steroids 2019; (150()):108426 doi:10.1016/j.steroids.2019.108426.

    PMID: 31228484
  18. 18

    Clinical Manifestations and Challenges in Adolescent and Adult Females With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Engberg H, Nordenström A, Hirschberg AL

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S37-S45 doi:10.1210/clinem/dgae696.

    PMID: 39836618
  19. 19

    Genetic characterization of a large cohort of Argentine 21-hydroxylase Deficiency.

    Fernández CS, Taboas M, Bruque CD, et al.

    Clinical endocrinology 2020; (93(1)):19-27 doi:10.1111/cen.14190.

    PMID: 32289882
  20. 20

    Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency.

    Grošelj U, Žerjav Tanšek M, Trebušak Podkrajšek K, et al.

    Acta chimica Slovenica 2016; (63(1)):33-7 doi:10.17344/acsi.2015.1797.

    PMID: 26970786
  21. 21

    Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.

    Sellick J, Aldridge S, Thomas M, Cheetham T

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(9)):1019-1022 doi:10.1515/jpem-2018-0260.

    PMID: 30173205
  22. 22

    Nonvirilized Genitalia in 3 Female Newborns With the Salt-Wasting Congenital Adrenal Hyperplasia Phenotype.

    Yauch L, Mayhew A, Gomez-Lobo V, et al.

    Journal of the Endocrine Society 2021; (5(1)):bvaa169 doi:10.1210/jendso/bvaa169.

    PMID: 33294764
  23. 23

    Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.

    Bonfig W, Roehl FW, Riedl S, et al.

    American journal of hypertension 2016; (29(2)):266-72 doi:10.1093/ajh/hpv087.

    PMID: 26071487
  24. 24

    Congenital Adrenal Hyperplasia.

    Fraga NR, Minaeian N, Kim MS

    Pediatrics in review 2024; (45(2)):74-84 doi:10.1542/pir.2022-005617.

    PMID: 38296783
  25. 25

    Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence

    Peltek Kendirci HN, Ünal E, Dündar İ, et al.

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.

    PMID: 39713876
  26. 26

    Treatment and Prevention of Adrenal Crisis and Family Education

    Çamtosun E, Sangün Ö

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):80-92 doi:10.4274/jcrpe.galenos.2024.2024-6-12-S.

    PMID: 39713905
  27. 27

    Adrenal insufficiency.

    Husebye ES, Pearce SH, Krone NP, Kämpe O

    Lancet (London, England) 2021; (397(10274)):613-629 doi:10.1016/S0140-6736(21)00136-7.

    PMID: 33484633
  28. 28

    Crinecerfont: First Approval.

    Lee A

    Drugs 2025; (85(6)):839-843 doi:10.1007/s40265-025-02165-1.

    PMID: 40240539
  29. 29

    Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.

    Sarafoglou K, Kim MS, Lodish M, et al.

    The New England journal of medicine 2024; (391(6)):493-503 doi:10.1056/NEJMoa2404655.

    PMID: 38828945

This page provides educational information about SV-CAH treatments and monitoring. Always consult your endocrinologist before adjusting medication doses or stress dosing protocols.

Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.